BMC Pharmacology & Toxicology

Scope & Guideline

Innovating the future of pharmacological sciences.

Introduction

Welcome to your portal for understanding BMC Pharmacology & Toxicology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationBMC PHARMACOL TOXICO / BMC Pharmacol. Toxicol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

BMC Pharmacology & Toxicology aims to advance knowledge in the fields of pharmacology and toxicology, focusing on drug action, safety, and therapeutic efficacy. The journal encompasses a wide range of studies related to drug development, pharmacokinetics, pharmacodynamics, and the toxicological assessment of substances.
  1. Pharmacokinetics and Drug Metabolism:
    Research exploring how drugs are absorbed, distributed, metabolized, and excreted in biological systems. This includes studies on population pharmacokinetics and drug-drug interactions.
  2. Toxicological Assessments:
    Investigations into the adverse effects of drugs and chemicals on biological systems, including in vivo and in vitro studies that assess safety and toxicology.
  3. Therapeutic Efficacy and Drug Development:
    Studies evaluating the effectiveness of pharmacological agents in treating various conditions, including comparative studies of drug formulations and dosages.
  4. Adverse Drug Reactions and Pharmacovigilance:
    Research focused on monitoring and analyzing adverse drug reactions, utilizing databases like the FDA Adverse Event Reporting System to improve drug safety.
  5. Innovative Drug Delivery Systems:
    Development and evaluation of novel drug delivery methods, including nanotechnology-based approaches to enhance therapeutic outcomes.
  6. Molecular Mechanisms of Drug Action:
    Exploration of the cellular and molecular pathways affected by drugs, including studies on signaling pathways and gene expression related to pharmacological effects.
BMC Pharmacology & Toxicology has identified several emerging themes and trends within its recent publications. These areas reflect current advancements in pharmacological research and the evolving landscape of drug safety and efficacy assessments.
  1. Integrated Pharmacovigilance Approaches:
    There is an increasing trend towards comprehensive pharmacovigilance studies that leverage big data analytics and real-world evidence to monitor drug safety and adverse reactions.
  2. Personalized Medicine and Pharmacogenomics:
    Research focusing on the genetic factors that influence drug metabolism and response is gaining traction, emphasizing the importance of tailoring treatments to individual patient profiles.
  3. Nanotechnology in Drug Delivery:
    The application of nanotechnology for drug delivery systems is emerging as a significant area of research, aimed at improving the bioavailability and therapeutic efficacy of medications.
  4. Investigating Drug Interactions:
    A growing emphasis on understanding complex drug-drug interactions, particularly in polypharmacy settings, is evident, reflecting the need for safer therapeutic regimens.
  5. Therapeutics in the Context of COVID-19:
    Research addressing the pharmacological management of COVID-19, including the evaluation of existing drugs and the development of novel therapeutic agents, has surged in relevance.
  6. Exploration of Natural Products and Traditional Medicine:
    There is an increasing interest in the pharmacological properties of natural products, with studies assessing their potential therapeutic effects and safety profiles.

Declining or Waning

While BMC Pharmacology & Toxicology has maintained a broad scope, certain themes have shown a decline in prominence over recent years. These waning areas may reflect shifts in research focus or emerging priorities in pharmacological and toxicological studies.
  1. Traditional Toxicology Studies:
    There has been a noticeable reduction in studies focused solely on classical toxicology without integrating modern methodologies such as molecular biology techniques or advanced in vivo models.
  2. In vitro Studies without Clinical Correlation:
    Research that relies exclusively on in vitro models without subsequent validation in clinical or real-world settings is becoming less common, as there is a growing emphasis on translational research.
  3. Single-Agent Pharmacology:
    Research focusing solely on the effects of single drugs is declining, with a shift towards studies that explore drug combinations, polypharmacy, or drug interactions.
  4. Animal Models with Limited Relevance to Human Health:
    The use of animal models that do not adequately mimic human pathophysiology is less favored, leading to a decline in studies employing outdated or less relevant models.
  5. Descriptive Epidemiology of Drug Use:
    Research that simply describes drug use patterns without addressing the implications for pharmacotherapy or toxicology is waning, as the field moves towards more analytical and intervention-based research.

Similar Journals

INDIAN JOURNAL OF PHARMACOLOGY

Advancing pharmacological knowledge for a healthier tomorrow.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Exploring the Synergy of Pharmacology and Molecular Medicine
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Elevating Standards in Drug Development Practices
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Drug Design Development and Therapy

Transforming Pharmaceutical Science with Cutting-Edge Insights
Publisher: DOVE MEDICAL PRESS LTDISSN: 1177-8881Frequency: 1 issue/year

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

Drug Research

Transforming Ideas into Therapeutic Realities
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Advances in Pharmacology and Pharmacy

Pioneering Discoveries in Drug Development
Publisher: HORIZON RESEARCH PUBLISHINGISSN: 2332-0036Frequency: 3 issues/year

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Advancing Knowledge at the Intersection of Medicine and Toxicology
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Iranian Journal of Pharmaceutical Research

Connecting scholars to elevate the standards of drug research.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

JOURNAL OF CLINICAL PHARMACOLOGY

Exploring the Frontiers of Pharmacological Research
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.